XTL-6865: Phase I data

In a dose-escalation, placebo-controlled Phase I trial in 32 HCV patients, XTL-6865 was safe. The trial involved 8 cohorts of 4 patients each, with 3 receiving XTL-6865 and 1 getting placebo. The firs...